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Abstract
Development of more sensitive imaging techniques has caused an increase in the number of diagnosed small renal tumors. Approximately 2–3% 
of these lesions are proved to be angiomyolipomas (AML), a rare benign tumor of the kidney sometimes causing pain and hematuria. The most 
required approach is observation, but in the case of recurrent symptoms or larger tumors, which may cause bleeding, a more active treatment is 
required. We present two cases of symptomatic AML tumors of different sizes in the kidney: one treated with transarterial embolization (TAE), 
and the other with percutaneous cryoablation (CRA). The lesions were diagnosed on the basis of contrast-enhanced computed tomography (CT) 
scan and magnetic resonance imaging (MRI). Both treatments proved to be effective and safe for treating renal AMLs. A follow-up carried out, 
based on contrast-enhanced CT scan, confirmed complete treatment of AML and decreased lesion size. There are myriad minimally invasive 
approaches for the treatment of renal AMLs, and the preservation of renal function remains a priority. The most popular treatment option is the 
selective renal artery embolization. Owing to its limited invasiveness, CRA could be an attractive option for the preventive treatment of AML.
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Renal angiomyolipoma (AML) is a benign mesenchymal 
tumor in its classic variant and comprises fat, smooth mus-
cle, and blood vessels. AML accounts for 0.3–3% of all renal 
masses (1, 2). AML belongs to the group of perivascular 
epithelioid cell tumors (3). Almost 80% AMLs are sporadic; 
remaining 20% are associated with the tuberous sclerosis 
syndrome (TSS) (4). 
Historically, 64% of AML were presented symptomati-
cally, most commonly with progressive flank pain, palpable 
mass, or rupture (5). Contemporary series now indicate that 
now AML are mostly asymptomatic and incidental lesions, 
and the increased use of cross-sectional imaging has led to 
rise in the diagnosis of these lesions (6). 
The diagnosis of AML approaches 100% sensitivity with 
computed tomography (CT) scan or ultrasound. The presence 
of fat within the lesion indicated on CT scan by a negative 
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attenuation of –10 Hounsfield units or lower, and the sono-
graphic appearance of a hyperechoic signal and acoustic shad-
owing, is pathognomonic of AML neoplasm (7). Absence of 
fat in a lesion does not necessarily exclude AML, as it could 
indicate a lipid-poor AML that can mimic renal cell carcinoma 
(RCC) (8). Biopsy is rarely required. The primary complica-
tion of AML is spontaneous bleeding in the retroperitoneum 
or into the collecting system (9). The risk of bleeding is related 
to the angiogenic component of tumor that includes irregular 
blood vessels (9), and the risk factors of bleeding are related to 
increase in tumor size (4). There are several options for man-
agement of AML: (1) active surveillance (AS); (2) selective 
arterial embolization (SAE) that can be used to devascular-
ize AMLs (10, 11); (3) surgical removal, preferably by neph-
ron-sparing surgery (NSS) (12); and (4) percutaneous ablation 
procedures, which is offered in selective patients (9, 13).
The systematic review undertaken by the European 
Association of Urology (EAU) Renal Cell Carcinoma 
Guidelines Panel found that AMLs are mostly managed by 
active surveillance as most of them do not grow (in 89% of 
cases) (14). Even if  they grow, their size increases very slowly 
and bleeding is a rare event (2.2%). Nevertheless, the 4-cm 
cut-off, traditionally used as an indication for active treat-
ment, could be reconsidered along with other factors such 
as patient’s age, rate of growth, and preference of treatment. 
The most frequently reported active treatment is surgery 
(31%), particularly NSS, followed by SAE (17%) (14). 
Embolization
Transarterial embolization (TAE) is a first line of treatment 
for active hemorrhage and symptomatic lesions. TAE is 
 associated with a mean 38.3% (–3.4 cm) reduction in AML 
size (10). The aim of embolization of AML is twofold: prox-
imal (upstream) embolization to reduce arterial inflow, and 
distal (tumor bed) embolization (15). A variety of embolic 
agents have been employed (foam, coil, or microparticle). 
However, retreatment proportion at 3 years is relatively high 
at 38% in a pooled analysis of multiple studies (16). 
Ablation
Ablation (percutaneous or laparoscopic) has been performed 
using a variety of techniques, such as radiofrequency abla-
tion (RFA), microwave ablation, and cryoablation (CRA), 
for tumors less than 6 cm in size (17). 
Castle et al. (18) report a complication rate of 13.3%, and 
both cryoablation and RFA have a low reintervention rate 
(0% at 3 years) (16). Although RFA appears to be safe in 
small- and medium-size renal AMLs, long-term efficacy data 
are lacking (8). 
Microwave ablation is a relatively novel type of thermal 
ablative procedure that has emerged in recent years; however, 
currently insufficient data exist on this modality for recom-
mending its routine use for renal AML (8). 
For the treatment of renal AMLs, cryoablation has been 
reported in two studies only with limited number of patients 
and short-term follow-up (19, 20). These studies indicate 
substantial progress in the use of cryoablation for the man-
agement of small renal masses (SRMs). Makki et al. have 
demonstrated that cryoablation appears to have a favor-
able complication profile. With absence of retreatment and 
a good preservation of renal function, it appears to be a 
safe and efficient long-term minimal invasive treatment for 
patients with subclinical renal AMLs to minimize the risk of 
potentially life-threatening hemorrhage (21).
This report presents two cases of symptomatic renal AML 
treated with two different techniques. 
Case Report 1
In September 2017, a 44-year-old female was admit-
ted to our hospital with 1-week history of  local left flank 
pain and macroscopic hematuria. Her laboratory findings 
such as complete blood cell count and creatinine demon-
strated no significant changes. The serum neuron-specific 
enolase was slightly increased as 24.59 ng/mL (normal 
range: 0–20  ng/mL). Other tumor markers (serum carbo-
hydrate antigen 125 [CA 125], CA 199, CA 153, CA 724, 
cytokeratin 19 [CK 19], carcinoembryonic antigen [CEA], 
and alpha-fetoprotein [AFP]) were within normal range. 
Contrast-enhanced CT scan revealed a 4.5×3.5×7.0-cm oval 
mass with heterogeneous density in based scan (CT value: 
17–40 HU), located in the left kidney (Figure 1). It con-
tained multiple foci with frank adipose density and a solid 
component with early and intense enhancement, referable to 
a renal AML with signs of  recent blood component and cel-
lular resentment. Abdominal MRI demonstrated the pres-
ence of  an expansive capsulated heterogeneous mass, with 
extension in the context of  renal parenchymal, and partial 
exophytic development in the context of  spleno-renal space, 
with high signal intensity on non-contrast T1-weighted 
images. It further demonstrated inhomogeneous low-to-high 
signal intensity on T2-weighted images due to blood content 
partly and foci of  internal fat. In the excretory phase, pres-
ence of  compressive effects was confirmed, with shift of  both 
upper/middle calyceal groups and renal pelvis (Figure  2). 
The patient was referred to the interventional radiology ser-
vice for a selective angiogram and embolization. After selec-
tive catheterization of the upper polar arteries of  the left 
kidney using a 5 French catheter, a branch was considered a 
potential feeder of  AML; hence, selective embolization was 
performed without complications. We used a liquid embolic 
agent, N- butyl cyanoacrylate-methacryloxy sulfolane 
(NBCA-MS; Glubran 2®; GEM Srl, Viareggio, Italy) with 
Lipiodol® (Guerbet, Aulnay-Sous-Bois, France) to make the 
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Figure 1: Contrast-enhanced CT scan in coronal reconstruction revealed a 4.5 × 3.5 × 7.0-cm renal AML located in the left 
 kidney, with signs of recent blood component and cellular resentment. 
(A) (B) (C)
(D) (E) (F)
Figure 2: Abdominal MRI demonstrated the presence of an expansive capsulated heterogeneous mass, with inhomogeneous 
low-to-high signal intensity on (A) T2-weighted images; (B) partial high-signal intensity on in-phase image; and (C) on opposed 
phase image due to blood content partly and foci of internal fat. (D–F) Subtracted images confirmed an enhancing component 
in mid-internal portion of mass.
glue radiopaque and modulate the delay of  polymerization 
(Figure 3). 
No significant change in creatinine levels appeared before 
and after the procedure. In the follow-up at 6 months of pro-
cedure, no bleeding area was observed and the AML was 
reduced. The patient remained without complaints 2 years 
after the procedure. The size of the left renal AML was indi-
cated by MRI to be reduced (Figure 4), with only a small 
residual portion vascularized and without damage to the 
healthy renal parenchyma. 
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Figure 3: (A) Digital subtraction angiography (DSA) showing a multi-lobulated aneurysm arising from one of the segmental 
branches of the left renal artery, which was the source of bleeding for this AML. (B–D) DSA obtained post-embolization with 




Figure 4: Two-year MRI control: (A, C) T1-weighted 
contrast- enhanced images, and (B, D) subtracted images 
demonstrated a reduced size of AML with only a small 
residual portion vascularized and without damage to healthy 
renal parenchyma.
Case Report 2
In March 2020, A 71-year-old female was referred for treat-
ment of an incidental right renal lesion in the presence of 
macroscopic hematuria. Her history included a lung adeno-
carcinoma with bone metastases in chemotherapy. Her labo-
ratory data such as complete blood cell count and creatinine 
demonstrated no significant CHANGES. For appearance of 
macroscopic hematuria, a contrast-enhanced CT scan was 
performed revealing a 3.0×2.7-cm oval mass with heteroge-
neous density in based scan located in the upper pole of the 
right kidney (Figure 5). It contained sporadic fat with a pro-
gressive enhancement observed in a major part of the tumor. 
Renal biopsy was performed and immunohistochemical find-
ings demonstrated that tumor cells were positive for smooth 
muscle actin (SMA) and melanocytic markers (human mel-
anoma black 45 [HBM-45] and Melan-A), and negative 
for desmin, cytokeratin 7 (CK 7), carbonic anhydrase IX 
(CAIX), and thyroid transcription factor-1 (TTF-1). The 
renal mass was diagnosed as AML. The patient was qualified 
for percutaneous cryoablation to reduce her symptoms. The 
procedure was performed under local anesthesia and deep 
sedation in the supine position. A total of five cryoprobes 
(BTG, Boston Scientific) of 17 G were placed into the target 
area, with assistance of combined CT and augmented infra-
red navigation system (SIRIO, MASMEC, Italy) (Figure 6) 
to cover the complete lesion and to spare as much normal 
parenchyma as possible. The control scan at the end of the 
procedure demonstrated a perirenal hematoma without 
active bleeding. The patient was discharged after 2 days of 
the procedure. All symptoms disappeared after 1 month 
of cryoablation; the CT control after 6 months demon-
strated complete necrosis area without residual viable tissue 
(Figure  7). In these 6 months, the values of renal function 
remained within the limits.
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(A) (B)
(C) (D)
Figure 5: Contrast-enhanced CT scan revealed a 3.0×2.7-cm 
oval mass in the upper pole of the right kidney with (A) het-
erogeneous density in based scan due to (B–D) sporadic fat 
foci and a progressive enhancement observed in the major 
part of the tumor.
(A) (B)
(C) (D)
Figure 6: CT scans in (A) axial and (B) coronal reconstruc-
tion during the procedure established the intralesional 
positioning of five cryoprobes and the dissection with air 
obtained to separate the bowel from the ablation zone. (C, D) 
CT scans at the end of the procedure depicted perirenal 
hematoma without active bleeding.
(A) (B)
(C) (D)
Figure 7: Contrast-enhanced CT scan after 6 months demon-
strated complete necrosis area without residual viable tissue.
Discussion
For the management of AML, active surveillance remains 
the first line of option in properly selected asymptomatic 
patients with small AMLs. However, some of them may 
cause symptoms like pain or hematuria and may require 
treatment. The frequency of symptoms increases with the 
size of the mass. Even if  the mass grows, its size increases 
very slowly and bleeding is a rare event (2.2%) (14). The 
most frequently reported active treatment is surgery (31%), 
particularly nephron-sparing surgery (NSS), followed by 
TAE (17%) (14). Ablative therapies are now utilized more 
to support renal function preservation and tumor control in 
short-term follow-up. Unfortunately, TAE is not free from 
complications. Although complexities connected with the 
injury of big vessels and renal failure are rare, but others 
such as post-embolization syndrome, meaning pain and ele-
vated temperature, occur in most patients (22). In the study 
conducted by Margulis et al. (23), the success rate was 70%, 
which, in the author’s opinion, can be increased by repeat-
ing the procedure. Kuusk et al. established the 3-year rate 
of freedom from reintervention after embolization to be 
63.5% and concluded that among treatment modalities, TAE 
was associated with a significant higher risk of reinterven-
tion (16). Makki et al. established in their study that cryoab-
lation requires no reintervention, with a minor complication 
rate of only 5.5% and a mean renal AML size reduction rate 
of 75.6% (21). When comparing current methods for treating 
renal AML, cryoablation appears to be an attractive alterna-
tive to TAE or partial nephrectomy. We decided to employ 
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TAE in the treatment of symptomatic AML measuring 
>4 cm, and CRA percutaneously in the treatment of small 
symptomatic AMLs. In such cases, dimension of the lesion 
is crucial for the choice of treatment, particularly controlling 
active bleeding in AML requires embolization. Although 
ablative options make the treatment of subclinical AML 
compelling, the goals of the treatment are to be defined in 
a better manner. Both the above-discussed techniques con-
tinue to evolve, and since the preservation of renal function 
remains a priority; modality selection must consider the clin-
ical context and the overall goals for individual patient. 
CONCLUSION
For the treatment of symptomatic AML, cryoablation 
appears to be a valid alternative to TAE or partial nephrec-
tomy. The choice of treatment must consider the preserva-
tion of renal function and the clinical context.
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